

New Editor

# New year, new editorial team

M N Rossor, M G Hanna

The New Year brings a change of editorship; after seven years of exceptional custodianship the journal says goodbye to Professor Chris Kennard. During his tenure he has maintained the key role of the journal as a premier European clinical neuroscience publication and witnessed an increase in submissions from about 1200 to over 2000 per annum. He has established online submissions via Bench>Press and established the website. He has overseen the introduction of *Neurology in Practice*, edited by Ian Bone and Geraint Fuller, which will continue in this series until 2005. A number of new features have been introduced, such as editorial commentaries. All of these provide added value to the quality of the submitted articles. It is this added value which is of such importance during the time of the information explosion and online publishing opportunities. These opportunities are indeed substantial, both to increase the amount

of information available but also to distribute journals to a wider audience at ever lower marginal cost. The danger, however, is that as quantity increases quality falls. Chris Kennard has met these challenges and hands over the journal in excellent shape.

## THE FUTURE

What of the future? *JNNP* was first published in 1938 (under the title of *Journal of Neurology and Psychiatry*) and the custodianship of such a journal is both an exciting challenge and a heavy responsibility. We reaffirm the aim of publishing the very best articles of clinical relevance in neurology, neurosurgery, and psychiatry. There are few clinical neuroscience journals that are as broadly based and it would be easy to focus just on neurology. However, we believe that this multidisciplinary nature is its strength, and indeed we hope to foster increased submissions in neurosurgery and psychiatry.

What then of the changes. "If it ain't broke don't mend it"; and so with a successful journal, changes in response to changing demands should occur with minimal fuss. We hope to raise the international profile of the journal and to this end there will be changes in the balance of the editorial team and details of this will follow in future issues. As always, we depend very much on the generosity and support, not only of the editorial board, but also of the large number of referees who assist with maintaining the quality of the journal. With increasing pressure of time and the increasing submission rate, this becomes ever more onerous, but without such freely given scholarship the journal cannot survive.

There is one change that is already apparent, namely the cover. We felt it was time for a change and the new cover highlights the three clinical subjects of neurology, neurosurgery, and psychiatry. The picture will change each month but what has not changed is the colour; *JNNP* remains "the green rag".

*J Neurol Neurosurg Psychiatry* 2004;**75**:1

## Authors' affiliations

Martin N Rossor, Michael G Hanna, Institute of Neurology, Queen Square, London WC1N 3BG, UK

Correspondence to: Professor Martin Rossor; mrossor@dementia.ion.ucl.ac.uk

Alzheimer's disease

# Contribution of cerebral amyloid angiopathy to Alzheimer's disease

S Love

## Contribution of CAA to Alzheimer's disease


In patients with Alzheimer's disease (AD), focal and diffuse ischaemic abnormalities of the cerebral white matter can be demonstrated neuropathologically<sup>1-3</sup> and neuroradiologically.<sup>4-8</sup> The focal lesions have been shown to contribute to motor and neuropsychiatric manifestations of AD,<sup>9-12</sup> and the more widespread or diffuse abnormalities to impaired cognition.<sup>13 14</sup> In some series, ischaemic cerebral lesions in AD have been more frequent in patients homozygous or heterozygous for the epsilon 4 (e4) allele of the apolipoprotein E gene (*APOE*),<sup>15-17</sup>

but other studies have found no such association.<sup>18-21</sup> Studies of the relation between white matter disease in patients with AD or probable AD, and the systemic manifestations of arteriosclerotic vascular disease, have yielded inconsistent findings.<sup>1 11 21-24</sup>

Several observations implicate cerebral amyloid angiopathy (CAA) as the probable cause of much of the white matter damage in AD. The vascular deposition of amyloid  $\beta$  protein ( $A\beta$ ) is much more frequent and tends to be much more severe in patients with AD than in age-matched controls.<sup>25-29</sup>

Furthermore, CAA is a well documented risk factor for cerebral infarction<sup>16 30-32</sup> and for focal and diffuse white matter ischaemic lesions.<sup>33-36</sup> The mechanisms whereby CAA may cause ischaemic damage to the white matter probably include a combination of luminal stenosis, endothelial damage, basement membrane thickening, thrombosis, loss of autoregulation, and vasospasm.<sup>37-40</sup> Because evidence of the involvement of CAA in AD is largely based on post-mortem studies, which are by their nature skewed towards end stage disease, it could be argued that any contribution of CAA may be confined to the terminal stages of disease. If this were true, it might be expected that an inverse relationship between the severity of CAA at autopsy and the duration of AD would be found. That this is not the case<sup>28</sup> suggests that CAA may exacerbate AD even at an early stage.

The occurrence of CAA in AD is strongly associated with possession of the e4 allele of *APOE*.<sup>17 28 32 41</sup> Indeed, possession of the e4 allele of *APOE* is much more strongly correlated with vascular than parenchymal deposition



**Figure 1** Tau immunopositive neurites clustered around a cortical artery with dyschoric amyloid angiopathy.

of A $\beta$ .<sup>28</sup> This may reflect on the pathogenesis of neurodegeneration in AD in patients with  $\epsilon 4$ . AD patients with severe CAA, almost all of whom possess at least one  $\epsilon 4$  allele, have significantly less parenchymal A $\beta$  than do patients with lesser degrees of CAA.<sup>28 42 43</sup> This is further evidence against the argument that CAA is simply a late manifestation of AD, and raises the possibility that CAA and parenchymal A $\beta$  have additive effects on the progression of clinical disease. Although the A $\beta$  within vessel walls could, in theory, also cause local neurotoxicity in the cerebral cortex, we have found no evidence of any associated reduction in the density of immunostaining of synaptophysin,<sup>44</sup> a sensitive marker of presynaptic integrity.

Observations of Weller and colleagues suggest that the involvement of CAA in AD may go beyond a contribution of ischaemia to the clinical and pathological manifestations of the disease, and that CAA may be involved in the development of plaques and tangles, the histological hallmarks of AD. Weller *et al*<sup>45 46</sup> propose that soluble A $\beta$  is normally eliminated from the brain

within interstitial fluid pathways that reach the cerebrospinal fluid in the subarachnoid space by passing along perivascular spaces in the cerebral cortex. If this model is correct, the obstruction to drainage of interstitial fluid caused by perivascular accumulation of amyloid could contribute to the accumulation of A $\beta$  within the parenchyma and the development of the plaques and tangles. Support for this comes from the occasional finding of tau immunopositive neurites clustered around larger arteries with dyschoric amyloid angiopathy (angiopathy in which amyloid extends from the affected blood vessels into the surrounding brain parenchyma) (fig 1). Although the flow of interstitial fluid within the perivascular space occurs in the opposite direction to that of the arterial blood flow, it may be enhanced by the pulsatile arterial distension. A failure of this propulsive mechanism has been proposed to explain the association of capillary CAA with thrombosis of overlying cortical arteries.<sup>47</sup>

However, several other observations indicate that the relationship between

CAA, plaques, and tangles is more complicated than would be predicted by a simple model of obstruction to drainage. These include the mutually exclusive topographical relationship between capillary CAA and extensive diffuse plaques,<sup>47</sup> and the inverse correlation between overall severity of amyloid angiopathy and parenchymal amyloid load in patients with moderate to severe CAA.<sup>28 43 45</sup> Further evidence suggests that soluble A $\beta$  within the brain is largely cleared by lipoprotein receptor related protein-1 mediated transcytosis across the endothelial cells of the blood-brain barrier.<sup>48</sup> Impaired clearance of A $\beta$  across the blood-brain barrier is probably central to the development of CAA in hereditary cerebrovascular amyloidosis with Dutch type haemorrhage<sup>49</sup> caused by a G $\rightarrow$ C transition at codon 693 of the  $\beta$  amyloid precursor protein gene.

Studies by Wyss-Coray *et al*<sup>43 50 51</sup> identify transforming growth factor  $\beta$  (TGF $\beta$ ) as a key influence on the relationship between parenchymal and vascular A $\beta$  in AD. TGF $\beta$ 1 levels are significantly increased in patients with

AD, not only in the cerebral cortex,<sup>52</sup> but also in the serum and CSF.<sup>53–54</sup> Chao *et al.*<sup>53</sup> observed a significant *in vivo* correlation between the level of TGFβ1 in the serum and the severity of dementia. On the face of it, this might seem paradoxical, as TGFβ1 has been shown to promote the clearance of Aβ from the parenchyma of transgenic mice expressing human β amyloid precursor protein.<sup>43</sup> However, in contrast to the beneficial effects of TGFβ1 on clearance of parenchymal amyloid, expression of TGFβ1 by astrocytes in transgenic mice actually induces deposition of amyloid in cerebral blood vessels, this being accelerated by co-expression of human β amyloid precursor protein.<sup>50–51</sup> A parallel can be drawn between the latter finding and the detection of severe CAA in regions of brain with markedly reduced parenchymal Aβ in a patient with AD who was immunized with Aβ (peptide fragment AN-1792).<sup>55</sup> The relevance of the observations of Wyss-Coray *et al.* to AD was strengthened by the authors' demonstration of a strong correlation between TGFβ1 mRNA levels and the severity of CAA in post-mortem brain tissue from 15 patients with AD and 7 controls.<sup>51</sup> However, while these post-mortem findings are of interest, it should be noted that the number of cases studied was small.

Many questions remain as to the relation between CAA and AD. Apart from ε4, the putative genetic risk factors for CAA show relatively little overlap with those for AD,<sup>56–57</sup> and despite the fact that ε4 is a major risk factor for CAA in AD and in patients presenting with cerebral haemorrhage, CAA is probably not associated with the *APOE* genotype if these conditions are excluded.<sup>29</sup> Although CAA is present in over 90% of patients with AD, it is not present in all cases and is therefore clearly not necessary for the development of the disease. Indeed, it is becoming increasingly clear that what we refer to as AD is really a spectrum of disorders with different genetic (and probably environmental) risk factors but having overlapping pathological and clinical phenotypes. For example, ε4 associated AD tends to be a disease with moderate to severe CAA, AD caused by some presenilin mutations is characterized by cotton wool plaques and pyramidal tract degeneration,<sup>58–63</sup> and AD in patients with an ε2 *APOE* allele and CAA carries an increased risk of parenchymal brain haemorrhage.<sup>64–65</sup>

The accurate diagnosis of CAA is likely to become increasingly important as we evaluate and implement treatments such as immunization, which are aimed at clearing parenchymal Aβ in AD, particularly if these carry a risk of

promoting vascular deposition of Aβ.<sup>65</sup> However, the ante-mortem diagnosis of CAA in AD remains a challenge. Measurement of plasma levels of Aβ and TGFβ was found to be unhelpful in predicting CAA.<sup>66</sup> For the time being, except in the relatively few patients who manifest with lobar cerebral haemorrhage<sup>67</sup> or have a brain biopsy,<sup>68–69</sup> we will have to continue to rely on examination of the brain at autopsy to make a confident diagnosis of CAA.

*J Neural Neurosurg Psychiatry* 2004;**75**:1–4

Correspondence to: Dr S Love, Department of Neuropathology, Institute of Clinical Neurosciences, Frenchay Hospital, Bristol BS16 1LE, UK; seth.love@bris.ac.uk

## REFERENCES

- Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. *Ann Neurol* 1986;**19**:253–62.
- Scheltens P, Barkhof F, Leys D, *et al.* Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. *Neurology* 1995;**45**:883–8.
- Tomimoto H, Akiyoshi I, Akiyama H, *et al.* Vascular changes in white matter lesions of Alzheimer's disease. *Acta Neuropathol* 1999;**97**:629–34.
- Catani M, Cherubini A, Howard R, *et al.* (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. *Neuroreport* 2001;**12**:2315–17.
- De Stefano N, Mortilla M, Federico A. Proton magnetic resonance spectroscopy of the brain in dementia. *Ital J Neurol Sci* 1999;**20**:S258–64.
- DeCarli C, Grady CL, Clark CM, *et al.* Comparison of positron emission tomography, cognition, and brain volume in Alzheimer's disease with and without severe abnormalities of white matter. *J Neural Neurosurg Psychiatry* 1996;**60**:158–67.
- Hanyu H, Sakurai H, Iwamoto T, *et al.* Diffusion-weighted MR imaging of the hippocampus and temporal white matter in Alzheimer's disease. *J Neurol Sci* 1998;**156**:195–200.
- Rose SE, Chen F, Chalk JB, *et al.* Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. *J Neural Neurosurg Psychiatry* 2000;**69**:528–30.
- Bennett DA, Gilley DW, Wilson RS, *et al.* Clinical correlates of high signal lesions on magnetic resonance imaging in Alzheimer's disease. *J Neurol* 1992;**239**:186–90.
- Bennett DA, Gilley DW, Lee S, *et al.* White matter changes: neurobehavioral manifestations of Binswanger's disease and clinical correlates in Alzheimer's disease. *Dementia* 1994;**5**:148–52.
- Hirono N, Kitagaki H, Kazui H, *et al.* Impact of white matter changes on clinical manifestation of Alzheimer's disease: A quantitative study. *Stroke* 2000;**31**:2182–8.
- O'Brien J, Perry R, Barber R, *et al.* The association between white matter lesions on magnetic resonance imaging and noncognitive symptoms. *Ann NY Acad Sci* 2000;**903**:482–9.
- Parnetti L, Tarducci R, Prescittini O, *et al.* Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. *Mech Ageing Dev* 1997;**97**:9–14.
- Amar K, Bucks RS, Lewis T, *et al.* The effect of white matter low attenuation on cognitive performance in dementia of the Alzheimer type. *Age Ageing* 1996;**25**:443–8.
- Bronge L, Farnaes SE, Blomberg M, *et al.* White matter lesions in Alzheimer patients are influenced by apolipoprotein E genotype. *Dement Geriatr Cogn Dis* 1999;**10**:89–96.
- Olichney JM, Hansen LA, Lee JH, *et al.* Relationship between severe amyloid angiopathy, apolipoprotein E genotype, and vascular lesions in Alzheimer's disease. *Ann NY Acad Sci* 2000;**903**:138–43.
- Premkumar DR, Cohen DL, Hedera P, *et al.* Apolipoprotein E-ε4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. *Am J Pathol* 1996;**148**:2083–95.
- Barber R, Gholkar A, Scheltens P, *et al.* Apolipoprotein E ε4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. *Arch Neurol* 1999;**56**:961–5.
- Doody RS, Azher SN, Haykal HA, *et al.* Does APO ε4 correlate with MRI changes in Alzheimer's disease? *J Neural Neurosurg Psychiatry* 2000;**69**:668–71.
- Hirono N, Yasuda M, Tanimukai S, *et al.* Effect of the apolipoprotein E epsilon4 allele on white matter hyperintensities in dementia. *Stroke* 2000;**31**:1263–8.
- Sawada H, Udaka F, Izumi Y, *et al.* Cerebral white matter lesions are not associated with apoE genotype but with age and female sex in Alzheimer's disease. *J Neural Neurosurg Psychiatry* 2000;**68**:653–6.
- Kawamura J, Meyer JS, Terayama Y, *et al.* Cerebral white matter perfusion in dementia of Alzheimer type. *Alz Dis Assoc Dis* 1991;**5**:231–9.
- Lopez OL, Becker JT, Rezek D, *et al.* Neuropsychiatric correlates of cerebral white-matter radiolucencies in probable Alzheimer's disease. *Arch Neurol* 1992;**49**:828–34.
- Blennow K, Wallin A, Uhlemann C, *et al.* White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. *Acta Neurol Scand* 1991;**83**:187–93.
- Yamada M, Tsukagoshi H, Otomo E, *et al.* Cerebral amyloid angiopathy in the aged. *J Neurol* 1987;**243**:371–6.
- Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. *Stroke* 1983;**14**:924–8.
- Esiri MM, Wilcock GK. Cerebral amyloid angiopathy in dementia and old age. *J Neural Neurosurg Psychiatry* 1986;**49**:1221–6.
- Chalmers K, Wilcock GK, Love S. APOE ε4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of Aβ protein. *Neuropathol Appl Neurobiol* 2003;**29**:231–8.
- Love S, Nicoll JA, Wilcock GK. APOE and cerebral amyloid angiopathy in the elderly. *Neuroreport* 2003;**14**:1535–6.
- Cadavid D, Mena H, Koeller K, *et al.* Cerebral β amyloid angiopathy is a risk factor for cerebral ischemic infarction. A case control study in human brain biopsies. *J Neuropathol Exp Neurol* 2000;**59**:768–73.
- Ellis RJ, Olichney JM, Thal LJ, *et al.* Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. *Neurology* 1996;**46**:1592–6.
- Olichney JM, Hansen LA, Hofstetter CR, *et al.* Association between severe cerebral amyloid angiopathy and cerebrovascular lesions in Alzheimer disease is not a spurious one attributable to apolipoprotein E4. *Arch Neurol* 2000;**57**:869–74.
- Gray F, Dubas F, Roulet E, *et al.* Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy. *Ann Neurol* 1985;**18**:54–9.
- Loes DJ, Biller J, Yuh WT, *et al.* Leukoencephalopathy in cerebral amyloid angiopathy: MR imaging in four cases. *Am J Neuroradiol* 1990;**11**:485–8.
- Yoshimura M, Yamanouchi H, Kuzuhara S, *et al.* Dementia in cerebral amyloid angiopathy: a clinicopathological study. *J Neurol* 1992;**239**:441–50.
- Haglund M, Englund E. Cerebral amyloid angiopathy, white matter lesions and Alzheimer encephalopathy - a histopathological assessment. *Dement Geriatr Cogn Disord* 2002;**14**:161–6.
- Crawford F, Suo Z, Fang C, *et al.* Characteristics of the in vitro vasoactivity of β-amyloid peptides. *Exp Neurol* 1998;**150**:159–68.
- Paris D, Town T, Parker TA, *et al.* Isoform-specific vasoconstriction induced by apolipoprotein E and

- modulation of this effect by Alzheimer's  $\beta$ -amyloid peptide. *Neurosci Lett* 1998;**256**:73–6.
- 39 **de Figueiredo RJ**, Oten R, Su J, *et al.* Amyloid deposition in cerebrovascular angiopathy. *Ann NY Acad Sci* 1997;**826**:463–71.
- 40 **Kalaria RN**. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. *Ann NY Acad Sci* 1999;**893**:113–25.
- 41 **Berg L**, McKeel DW Jr, Miller JP, *et al.* Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. *Arch Neurol* 1998;**55**:326–35.
- 42 **Weller RO**, Massey A, Kuo YM, *et al.* Cerebral amyloid angiopathy: accumulation of A $\beta$  in interstitial fluid drainage pathways in Alzheimer's disease. *Ann NY Acad Sci* 2000;**903**:110–7.
- 43 **Wyss-Coray T**, Lin C, Yan F, *et al.* TGF- $\beta$ 1 promotes microglial amyloid- $\beta$  clearance and reduces plaque burden in transgenic mice. *Nat Med* 2001;**7**:612–18.
- 44 **Chalmers K**, Wilcock GK, Love S. Cerebral amyloid angiopathy in Alzheimer's disease does not influence neocortical synaptic density or subcortical white matter accumulation of  $\beta$ -amyloid precursor protein. *Neuropathol Appl Neurobiol* 2003;**29**:184.
- 45 **Weller RO**, Massey A, Newman TA, *et al.* Cerebral amyloid angiopathy: amyloid  $\beta$  accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. *Am J Pathol* 1998;**153**:725–33.
- 46 **Preston SD**, Steart PV, Wilkinson A, *et al.* Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid  $\beta$  from the human brain. *Neuropathol Appl Neurobiol* 2003;**29**:106–17.
- 47 **Weller RO**, Yow HY, Preston SD, *et al.* Cerebrovascular disease is a major factor in the failure of elimination of A $\beta$  from the aging human brain: implications for therapy of Alzheimer's disease. *Ann NY Acad Sci* 2002;**977**:162–8.
- 48 **Shibata M**, Yamada S, Kumar SR, *et al.* Clearance of Alzheimer's amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. *J Clin Invest* 2000;**106**:1489–99.
- 49 **Monro OR**, Mackic JB, Yamada S, *et al.* Substitution at codon 22 reduces clearance of Alzheimer's amyloid- $\beta$  peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. *Neurobiol Aging* 2002;**23**:405–12.
- 50 **Wyss-Coray T**, Lin C, Sanan DA, *et al.* Chronic overproduction of transforming growth factor- $\beta$ 1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. *Am J Pathol* 2000;**156**:139–50.
- 51 **Wyss-Coray T**, Masliah E, Mallory M, *et al.* Amyloidogenic role of cytokine TGF- $\beta$ 1 in transgenic mice and in Alzheimer's disease. *Nature* 1997;**389**:603–6.
- 52 **Luterman JD**, Haroutunian V, Yemul S, *et al.* Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. *Arch Neurol* 2000;**57**:1153–60.
- 53 **Chao CC**, Ala TA, Hu S, *et al.* Serum cytokine levels in patients with Alzheimer's disease. *Clin Diagn Lab Immunol* 1994;**1**:433–6.
- 54 **Chao CC**, Hu S, Frey WH 2nd, *et al.* Transforming growth factor  $\beta$  in Alzheimer's disease. *Clin Diagn Lab Immunol* 1994;**1**:109–10.
- 55 **Nicoll JA**, Wilkinson D, Holmes C, *et al.* Neuropathology of human Alzheimer disease after immunization with amyloid- $\beta$  peptide: a case report. *Nat Med* 2003;**9**:448–52.
- 56 **Yamada M**. Risk factors for cerebral amyloid angiopathy in the elderly. *Ann NY Acad Sci* 2002;**977**:37–44.
- 57 **Yamada M**, Sodeyama N, Itoh Y, *et al.* Association of neprilysin polymorphism with cerebral amyloid angiopathy. *J Neurol Neurosurg Psychiatry* 2003;**74**:749–51.
- 58 **Brooks WS**, Kwok JB, Kril JJ, *et al.* Alzheimer's disease with spastic paraparesis and 'cotton wool' plaques: two pedigrees with PS-1 exon 9 deletions. *Brain* 2003;**126**:783–91.
- 59 **Tabira T**, Chui de H, Nakayama H, *et al.* Alzheimer's disease with spastic paresis and cotton wool type plaques. *J Neurosci Res* 2002;**70**:367–72.
- 60 **Steiner H**, Revesz T, Neumann M, *et al.* A pathogenic presenilin-1 deletion causes aberrant A $\beta$ 42 production in the absence of congophilic amyloid plaques. *J Biol Chem* 2001;**276**:7233–9.
- 61 **O'Riordan S**, McMonagle P, Janssen JC, *et al.* Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. *Neurology* 2002;**59**:1108–10.
- 62 **Verkkoniemi A**, Kalimo H, Paetau A, *et al.* Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype. *J Neuropathol Exp Neurol* 2001;**60**:483–92.
- 63 **Houlden H**, Baker M, McGowan E, *et al.* Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid- $\beta$  concentrations. *Ann Neurol* 2000;**48**:806–8.
- 64 **Nicoll JA**, Burnett C, Love S, *et al.* High frequency of apolipoprotein E  $\epsilon$ 2 allele in hemorrhage due to cerebral amyloid angiopathy. *Ann Neurol* 1997;**41**:716–21.
- 65 **McCarron MO**, Nicoll JA. Apolipoprotein E genotype and cerebral amyloid angiopathy-related hemorrhage. *Ann NY Acad Sci* 2000;**903**:176–9.
- 66 **Greenberg SM**, Cho HS, O'Donnell HC, *et al.* Plasma  $\beta$ -amyloid peptide, transforming growth factor- $\beta$ 1, and risk for cerebral amyloid angiopathy. *Ann NY Acad Sci* 2000;**903**:144–9.
- 67 **Knudsen KA**, Rosand J, Karluk D, *et al.* Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. *Neurology* 2001;**56**:537–9.
- 68 **Greenberg SM**, Vonsattel JP. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. *Stroke* 1997;**28**:1418–22.
- 69 **McCarron MO**, Nicoll JA, Love S, *et al.* Surgical intervention, biopsy and APOE genotype in cerebral amyloid angiopathy-related haemorrhage. *Br J Neurosurg* 1999;**13**:462–7.

Alzheimer's disease

## Cognitive profiles in Alzheimer's disease

N A Johnson

### Diagnosing vascular dementia

In the paper by Graham *et al* (see pp 61–71, this issue) the authors provide a useful foundation for delineating the neuropsychological profile of a well defined group of subjects with vascular dementia and for differentiating this profile from that typically associated with Alzheimer's disease. One of the main weaknesses in previous studies that attempted to characterise the neuropsychological profile of subjects with vascular dementia has been the within group heterogeneity. Unlike Alzheimer's disease, in which well established, validated diagnostic criteria exist, multiple

clinical criteria for the diagnosis of vascular dementia have been proposed.<sup>2</sup> Acceptable sensitivity and specificity for the detection of vascular dementia in clinical practice have yet to be established for any of the proposed clinical criteria,<sup>3</sup> and application of different criteria has resulted in wide variations in the prevalence of vascular dementia.<sup>4</sup> The primary focus in establishing clinical criteria for vascular dementia has been the identification of vascular factors; relevant neuroimaging findings, focal neurological signs, and establishing a temporal relationship between

symptoms and cerebrovascular events, although minimal attention has been paid to defining the dementia in vascular dementia. Similar to clinical features used to define Alzheimer's disease dementia, the clinical symptoms required for the identification of dementia in vascular dementia frequently emphasise memory impairment as the primary criterion. However, despite the limitations of previous research due to the lack of uniform diagnostic criteria, as well as the individual variability associated with cerebrovascular disease, the most consistent finding that has emerged regarding the neuropsychological profile in vascular dementia has been the relative preservation of memory functioning as compared with subjects with Alzheimer's disease.<sup>5</sup> This finding, as well as other characteristic neuropsychological impairments as described in the current study, may eventually lead to an improvement in the ability to accurately diagnose vascular dementia in the clinical setting. Continued research is needed in this area, including clinicopathological studies, to further refine the clinical

profile in vascular dementia and improve the specificity of diagnostic criteria.

*J Neurol Neurosurg Psychiatry* 2004;**75**:4–5

Correspondence to: N A Johnson, Cognitive Neurology & Alzheimer's Disease Center, Northwestern University Medical School, 320 East Superior Street, Suite 11-499, Chicago, IL 60611, USA; johnson-n@northwestern.edu

REFERENCES

- 1 **Graham NL**, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia. *J Neurol Neurosurg Psychiatry* 2003;**74**:61–71.
- 2 **Roman GC**, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. *Neurology* 1993;**43**:250–60.

- 3 **Knopman DS**, Parisi JE, Boeve BF, et al. Vascular dementia in a population-based autopsy study. *Arch Neurol* 2003;**60**:569–75.
- 4 **Chui HC**, Mack W, Jackson JE, et al. Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability [see comments]. *Archives of Neurology* 2000;**57**:191–6.
- 5 **Looi J**, Sachdev P. Differentiation of vascular dementia from AD on neuropsychological tests. *Neurology* 1999;**53**:670–8.

Depression and cognitive decline

# Depressive symptoms and cognitive decline—disentangling the effect of affect

R Stewart

## Time to take depression seriously?

Is depression a risk factor for cognitive decline? Dementia, a potential consequence of cognitive decline, is a devastating disorder. If depression is a risk factor, it is important because it is common. Therefore, even a weak risk–outcome association might represent a substantial population level impact and “account for” a large number of dementia cases. It is not surprising that a growing body of observational research has sought to address this question, including the analysis by Wilson *et al* in this issue (pp 126–9).<sup>1</sup> However, unfortunately we are still a long way from establishing causation and measurements of exposure leave a lot to be desired.

Several prospective studies have shown that depressive symptoms are associated with an increased risk of developing dementia.<sup>2</sup> It is possible that depression may actually initiate or accelerate neurodegenerative processes. This is obviously of particular interest given the implied possibility of preventing cognitive decline and dementia. However, there are other potential explanations. Depression may simply be a reaction to a perceived deterioration in cognitive function. Alternatively, cognitive function may be impaired during a depressive episode because of reduced

attention and motivation, so that someone may present with apparent clinical dementia at a relatively early stage of neurodegeneration. These two explanations are addressed in the analysis carried out by Wilson *et al* and are not supported by their findings because increased baseline depressive symptoms predicted cognitive decline independently of baseline cognitive function. A third explanation is that depression is a prodromal symptom of dementia rather than a risk factor. This hypothesis is less easy to test. It would predict a greater level of neurodegenerative pathology associated with depressive symptoms in people without clinical dementia in life. However, population based pathological data are hard to come by. Wilson *et al* cite a report in press at the time of submission<sup>3</sup> which may shed light on this issue but further research is likely to be required.

So where to go from here? A disappointing feature of most research in this area has been the simplistic approach to depression as an exposure. Some studies focus on categories such as major depression, which poorly characterise late life affective disorder.<sup>4</sup> Most, including that by Wilson *et al*, do not investigate depression but depressive symptoms. But can a person's mood

state be adequately reflected by summing up a short list of symptoms? What about the pervasiveness of individual symptoms themselves, their nature (such as the type of sleep disturbance) or underlying clustering (for example, motivation and affect)? Levels of affective disturbance fluctuate throughout the life course and are likely to have complex, interdependent relations with other aspects of health, such as cognitive function and somatic states (for example, vascular disease).<sup>5</sup> Secondary analyses of high quality longitudinal datasets have undoubtedly made substantial contributions to this research field, but are invariably limited by measurements that have to cover a large number of objectives. Dysphoric symptoms predict a wide variety of adverse outcomes but are rarely measured in any detail. Perhaps it is time to take depression seriously.

*J Neurol Neurosurg Psychiatry* 2004;**75**:5.  
doi: 10.1136/jnnp.2003.028399

Author's affiliation

R Stewart, Institute of Psychiatry, Denmark Hill, London SE5 8AF, UK;  
r.stewart@iop.kcl.ac.uk

REFERENCES

- 1 **Wilson RS**, Mendes de Leon CF, Bennett DA, et al. Depressive symptoms and cognitive decline in a community population of older persons. *J Neurol Neurosurg Psychiatry* 2004;**75**:126–9.
- 2 **Geerlings MI**, Schoevers RA, Beekman ATF, et al. Depression and risk of cognitive decline and Alzheimer's disease. Results of two prospective community-based studies in the Netherlands. *Br J Psychiatry* 2000;**176**:568–75.
- 3 **Wilson RS**, Schneider JA, Bienias JL, et al. Depressive symptoms, clinical AD, and cortical plaques and tangles in older persons. *Neurology* (in press).
- 4 **Snowdon J**. Epidemiologic questions on mood disorders in old age. *Clin Neurosci* 1997;**4**:3–7.
- 5 **Stewart R**. The interface between cerebrovascular disease, dementia and depression. In: Chiu E, Ames D, Katona C, eds. *Vascular disease and affective disorders*. London: Martin Dunitz, 2002.